Alpha-Synuclein and Its Impact on Neurodegeneration and Brain Connectivity: A Survey

Abstract

Alpha-synuclein (-syn) is a pivotal protein implicated in the pathogenesis of synucleinopathies, including Parkinson's disease (PD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB). Its misfolding and aggregation into toxic oligomers and fibrils disrupt cellular homeostasis, leading to neurotoxicity and the propagation of pathology within neural networks. This survey provides a comprehensive overview of -syn's physiological roles and pathological implications, emphasizing its impact on the autonomic nervous system (ANS) and brain connectivity. The survey highlights the significance of -syn as a potential biomarker for early diagnosis and differentiation of synucleinopathies, given the current lack of definitive biomarkers. Recent research underscores the potential influence of the gut-brain axis and microbial amyloids on -syn aggregation, suggesting novel therapeutic avenues targeting gut health. The integration of advanced computational techniques, such as machine learning and network analysis, offers new insights into the complex brain networks affected by -syn pathology, facilitating the development of targeted interventions. Future research should focus on refining models, exploring additional imaging biomarkers, and integrating brain connectivity metrics with regional EEG statistics to enhance diagnostic accuracy and therapeutic strategies. Understanding the critical link between DNA damage and neurodegenerative processes further underscores the importance of DNA quality control in maintaining neuronal integrity. By addressing these key areas, future research can advance the development of effective treatments for synucleinopathies, ultimately improving patient outcomes and quality of life.

1 Introduction

1.1 Overview of Alpha-Synuclein in Neurodegenerative Diseases

Alpha-synuclein (-syn) is a presynaptic neuronal protein critically involved in the pathogenesis of neurodegenerative disorders, particularly synucleinopathies like Parkinson's disease (PD). Its misfolding and aggregation result in Lewy bodies, key pathological features of PD [1], and are associated with mitochondrial dysfunction, significantly contributing to neuronal degeneration [2].

Functionally, -syn regulates dopamine neurotransmission, essential for motor control and synaptic integrity [3]. The transition from its normal role to a pathological state involves complex mechanisms, including disruptions in cellular pathways and mitochondrial function [2]. Its interaction with cellular membranes is believed to exacerbate synaptic dysfunction and neuronal death [3].

Recent studies have highlighted -syn's potential as a biomarker for the early diagnosis and differentiation of PD and other synucleinopathies, addressing the current lack of definitive biomarkers [4]. Genetic investigations have identified mutations and duplications in the SNCA gene, including a 21-nucleotide duplication linked to juvenile-onset synucleinopathy, which presents unique -syn inclusions [1].



Figure 1: chapter structure

This survey also explores the intricate genotype-phenotype relationships and common cellular pathways emerging from genetic and mechanistic studies in neurodegenerative diseases [5]. Additionally, the role of microglia, the central nervous system's resident immune cells, is pivotal in both health and neurodegenerative conditions, potentially influencing the progression of -syn pathology [2].

The survey aims to provide a comprehensive examination of -syn's physiological functions and its detrimental effects in synucleinopathies, particularly PD. It emphasizes the urgent need for systematic investigations into the role of -syn aggregates in early synaptic dysfunction and neurodegeneration, as well as the advancement of diagnostic techniques and therapeutic strategies targeting pathogenic -syn conformations, including toxic oligomers [6, 7].

1.2 Significance of Studying Alpha-Synuclein's Impact

Studying alpha-synuclein (-syn) is vital due to its central role in the pathogenesis of synucleinopathies, such as Parkinson's disease (PD) and multiple system atrophy (MSA), which significantly compromise health-related quality of life [8]. The aggregation of -syn is a critical focus in this survey, with profound implications for PD pathogenesis [1]. Understanding the mechanisms by which -syn aggregation and stress activate the DNA damage response (DDR) in vivo is essential for elucidating its role in neurodegeneration [2]. Furthermore, the incomplete understanding of -syn's physiological roles and its complex interactions with cellular components remain significant challenges in this field [9].

The propagation of -syn among neurons contributes to neurodegeneration in synucleinopathies, highlighting the need for improved diagnostic markers due to the extended prodromal period associated with these diseases. Insights into -syn's transmission may open new avenues for therapeutic interventions [4]. The shared clinical and pathological features of neurodegenerative disorders, alongside distinct mechanisms driving their progression, underscore the importance of studying -syn's impact [10].

Moreover, accurately identifying metabolic connectivity patterns at the individual level in PD poses challenges for effective diagnosis and understanding of the disease [11]. This issue is compounded by the absence of a unified framework to link connectome alterations across multiple disorders, hindering the comprehension of shared biological mechanisms [12]. Addressing these knowledge gaps will enhance our understanding of -syn's impact on neurodegeneration and brain connectivity,

ultimately leading to improved therapeutic strategies and diagnostic methods.The following sections are organized as shown in Figure 1.

2 Background and Core Concepts

2.1 Alpha-Synuclein and Its Physiological Roles

Alpha-synuclein (-syn) is integral to neuronal health, particularly in regulating neurotransmitter release and synaptic plasticity, which are vital for cognitive and motor functions [6]. Its structure, featuring distinct N-terminal and C-terminal domains, facilitates interactions with cellular membranes, crucial for maintaining dopamine neurotransmission and synaptic integrity. This structural diversity allows -syn to exist in monomeric, oligomeric, and fibrillar forms, each associated with different functional roles [13]. While monomers are linked to normal physiological functions, oligomers and fibrils are associated with neurodegenerative conditions, emphasizing -syn's role in neurotransmitter systems [14].

Recent research highlights -syn's potential as a biomarker for neurodegenerative diseases, necessitating a deeper understanding of its physiological roles in disease progression and diagnosis [15]. Advanced computational methods, including machine learning and Bayesian inference, combined with connectomic data, provide new insights into the complex brain networks associated with Parkinson's disease, further elucidating -syn's functions [16]. Ongoing research continues to categorize -syn's interactions and functions, enhancing our understanding of its critical role in the nervous system [17].

Network analyses derived from neuroimaging data offer a framework for understanding anatomical and functional brain networks, essential for predicting clinical syndromes resulting from neuropathology [18]. This approach aligns with the broader framework of network science, emphasizing the need to consider both structural and functional aspects of neural connectivity [5].

2.2 Pathological Implications of Alpha-Synuclein

Alpha-synuclein (-syn) is central to the pathology of neurodegenerative diseases, particularly synucleinopathies like Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB). Its tendency to misfold and form toxic aggregates disrupts cellular homeostasis, inducing neurotoxicity [9]. These aggregates activate the DNA damage response (DDR) in dopaminergic neurons, contributing to neuronal degeneration and complicating efforts to mitigate -syn accumulation and propagation across neurons.

The aggregation mechanisms of -syn are complex, influenced by its interactions with cellular membranes. The dynamic nature of intrinsically disordered proteins (IDPs) like -syn complicates these interactions, crucial for understanding its amyloidogenic properties [3]. Current biophysical methods and simulations often fail to capture the full spectrum of -syn conformational states, hindering the elucidation of its pathological roles [3]. Additionally, the interplay between aggregation and degradation mechanisms remains poorly understood, complicating therapeutic development for PD [19].

Genetic factors significantly influence -syn pathology, with mutations in the SNCA gene linked to juvenile-onset synucleinopathy and altered aggregation patterns [1]. Epigenetic modifications, such as DNA methylation within SNCA intron 1 CGI, further contribute to the pathogenesis of PD and DLB, highlighting the multifaceted nature of -syn pathology [20].

Structural and functional alterations in brain connectivity driven by -syn aggregation are critical to understanding neurodegenerative disease progression. Changes in cortical geometry and network topology in PD may serve as potential disease markers [21]. The JSSE method, revealing individual neurophysiological details and metabolic connectivity variations, is vital for diagnosing PD [11].

External factors, such as microbial amyloids, may exacerbate -syn aggregation, implicating gut microbiota in PD pathology [22]. This underscores the need for comprehensive research strategies to address the multifaceted challenges posed by -syn's pathological implications [17]. Understanding these complex interactions is essential for developing targeted therapies and improving diagnostic techniques for neurodegenerative diseases.

2.3 Interconnections Between Key Concepts

The intricate interplay between alpha-synuclein (-syn), synucleinopathies, neurodegeneration, and brain connectivity is crucial for understanding the pathophysiology of these disorders. -syn's normal role in synaptic function and neurotransmission becomes pathological upon misfolding, leading to toxic oligomer formation central to synucleinopathies like Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB). These aggregates disrupt cellular homeostasis, triggering neurodegenerative processes characterized by synaptic dysfunction and neuroinflammation, intricately linked to alterations in brain connectivity, as the pathological spread of -syn affects structural and functional interconnections between brain regions [5].

Graph theory and network science have been effectively integrated into neuroscience, elucidating the evolution and disruption of these connections in disease states. Network analysis represents a significant advancement over previous methods by illustrating multi-scale relationships within and between neural systems, genes, and behaviors. This approach highlights the hierarchical modular organization of the connectome, influencing the transition between synchronous and asynchronous states and underscoring the complexity of brain network dynamics [23].

The co-occurrence of -syn pathology with other neurodegenerative conditions necessitates comprehensive diagnostic strategies that consider multiple interacting pathologies. Advanced imaging techniques and computational models, such as network object statistics (NOS), facilitate detailed analysis of brain imaging data, linking structural and functional changes to specific symptomatology [24]. Understanding these complex interactions is essential for developing targeted therapies and enhancing diagnostic techniques for neurodegenerative diseases.

The exploration of synucleinopathies has garnered significant attention in recent years, particularly in relation to the pathological role of alpha-synuclein. This review aims to elucidate the complex interactions and implications of alpha-synuclein in various neurodegenerative diseases. As illustrated in Figure 2, the hierarchical structure of alpha-synuclein's role in synucleinopathies is depicted, emphasizing its involvement in Parkinson's Disease, Multiple System Atrophy, and Dementia with Lewy Bodies. The figure categorizes the mechanisms of aggregation, neurotoxicity, and transmission, while also addressing current therapeutic strategies and the challenges that accompany them. This visual representation not only enhances our understanding of the multifaceted nature of alpha-synuclein but also serves as a valuable reference point for discussing the implications of these findings in the context of ongoing research and treatment development.

3 Alpha-Synuclein and Synucleinopathies

3.1 Role of Alpha-Synuclein in Parkinson's Disease

Parkinson's disease (PD) pathogenesis is intricately linked to alpha-synuclein (-syn) misfolding and aggregation, forming neurotoxic oligomers and fibrils that impair neuronal function [25]. These aggregates are pivotal in Lewy body formation, exacerbating mitochondrial dysfunction and neuronal damage [23]. The transition of -syn from monomeric to oligomeric and fibrillar forms is central to its neurotoxic effects and correlates with the progression of parkinsonian phenotypes [23]. Gut microbiota may influence PD pathogenesis by affecting -syn aggregation, suggesting novel therapeutic avenues [26]. Identifying distinct PD subtypes based on clinical features and brain network metrics underscores the complexity of -syn's role and the necessity for personalized therapeutic strategies [23].

Therapeutic strategies targeting -syn aggregation are under exploration. Graphene quantum dots (GQDs) have shown efficacy in preventing -syn aggregation and protecting against neuronal death [27]. Monoclonal antibodies like 1H7 have demonstrated potential in reducing -syn accumulation and associated behavioral deficits in preclinical models [28]. Advances in computational modeling, such as the Deep and Wide Multiscale Recursive Network (DAWMR) and Multilayer Perceptron (MLP), provide insights into synaptic connections affected by -syn pathology, enhancing understanding of disease progression [29]. The brain metabolic network in PD reveals distinct pathophysiological mechanisms, offering potential biomarkers for differentiating PD from healthy controls and elucidating -syn's role in the disease [11]. The neuroprotective effects of PPAR observed in both preclinical models and clinical trials further support the development of targeted interventions for PD [30].



Figure 2: This figure illustrates the hierarchical structure of alpha-synuclein's role in synucleinopathies, highlighting its involvement in Parkinson's Disease, Multiple System Atrophy, and Dementia with Lewy Bodies. It categorizes the mechanisms of aggregation, neurotoxicity, and transmission, along with current therapeutic strategies and challenges.

Understanding -syn's role as a prion-like agent in PD progression through toxic oligomer formation and intercellular transmission is crucial for developing diagnostic tools and therapeutic strategies targeting aggregated forms of -syn, which are currently being investigated in clinical trials [17, 7, 4]. A comprehensive understanding of -syn interactions within the neuronal environment is essential for effective interventions against PD.

3.2 Mechanisms of Aggregation and Neurotoxicity

The aggregation of alpha-synuclein (-syn) into toxic oligomers and fibrils is central to its neurotoxic effects, significantly contributing to Parkinson's disease (PD) and other synucleinopathies. As illustrated in Figure 3, this figure categorizes the aggregation mechanisms into toxic oligomers and fibril structures, while also exploring the neurotoxic effects such as neuronal stress and membrane disruption. Advanced techniques, such as cryo-electron microscopy, have elucidated the structural details of these aggregates, enhancing understanding of their role in disease [31]. The conformational diversity of -syn, observed through Atomic Force Microscopy (AFM), reveals distinct monomeric, oligomeric, and fibrillar states, each impacting neuronal health differently [32]. Oligomeric forms of -syn are particularly neurotoxic, exacerbating neuronal cell stress and inflammation more than fibrils [7]. These oligomers disrupt cellular homeostasis by impairing membrane integrity and mitochondrial function, contributing to neuronal dysfunction [33]. Notably, -syn's dual role in promoting SNARE complex assembly while potentially inhibiting membrane fusion underscores its complex involvement in synaptic dysfunction [34].

Current therapeutic approaches face challenges in effectively inhibiting -syn fibrillization and disaggregating existing fibrils [27]. The figure also outlines these therapeutic challenges, including the need to address patient subtypes in treatment strategies. However, innovative methods, including the systemic administration of the 1H7 monoclonal antibody, have shown promise in reducing -syn accumulation and propagation in synucleinopathy models [28]. The classification of PD patients into distinct subtypes using brain imaging data and Joint Independent Component Analysis (JICA) highlights the heterogeneity of -syn pathology and its implications for personalized treatment strategies [35]. Understanding the mechanisms of -syn aggregation and its neurotoxic effects remains crucial for developing targeted interventions aimed at mitigating its impact on neuronal health and disease progression [6].



Figure 3: This figure illustrates the mechanisms of alpha-synuclein aggregation and its neurotoxic effects, highlighting the challenges in developing therapeutic strategies. It categorizes the aggregation into toxic oligomers and fibril structures, explores neurotoxic effects such as neuronal stress and membrane disruption, and outlines therapeutic challenges including inhibiting fibrillization and addressing patient subtypes.

3.3 Alpha-Synuclein in Multiple System Atrophy and Dementia with Lewy Bodies

Alpha-synuclein (-syn) significantly contributes to synucleinopathies beyond Parkinson's disease, particularly in Multiple System Atrophy (MSA) and Dementia with Lewy Bodies (DLB). In MSA, -syn aggregates predominantly in oligodendrocytes, resulting in widespread neurodegeneration and diverse clinical manifestations. Recent studies have identified five distinct subphenotypes of MSA progression, highlighting the disease's heterogeneity and its clinical implications [36]. The abnormal accumulation of -syn in MSA and DLB is marked by its aggregation into glial cytoplasmic inclusions and Lewy bodies, respectively, distinguishing these disorders from other neurodegenerative diseases [10]. Unique mutations in the SNCA gene, leading to novel -syn conformations, provide insights into the molecular mechanisms underlying these synucleinopathies [37]. Understanding these mechanisms is vital for developing targeted interventions to modulate -syn aggregation and mitigate neurotoxic effects.

In DLB, -syn pathology is associated with cognitive decline and neuropsychiatric symptoms, complicating disease management. The overlap of -syn pathology in MSA and DLB with other neurodegenerative conditions necessitates comprehensive diagnostic strategies that account for the multifaceted nature of these disorders. The natural history of health-related quality of life (Hr-QoL) in MSA has been successfully described, offering valuable insights for patient management and care [8]. Such insights are crucial for developing personalized treatment plans that address the specific needs of MSA and DLB patients, ultimately enhancing their quality of life and clinical outcomes.

3.4 Transmission and Spread of Alpha-Synuclein Pathology

The propagation of alpha-synuclein (-syn) pathology within the brain is a critical factor in the progression of synucleinopathies, including Parkinson's disease (PD) and Multiple System Atrophy (MSA). The prion-like spread of -syn aggregates is increasingly recognized as a key mechanism driving neurodegeneration in these disorders [10]. This process involves the transmission of misfolded -syn from affected neurons to neighboring cells, promoting the formation of toxic aggregates that compromise cellular function.

Lysosomal exocytosis has been proposed as a mechanism for the release of pathogenic -syn species into the extracellular space, facilitating their spread across neural networks [38]. This pathway emphasizes the importance of cellular clearance systems in regulating -syn pathology and highlights potential therapeutic targets for mitigating disease progression. Cerebrospinal fluid (CSF) biomarkers provide insights into the transmission dynamics of -syn pathology. Elevated levels of CSF total tau (t-tau) and reduced amyloid-beta (A) 1-42 correlate with increased cerebral amyloid and synuclein pathology in Lewy body disorders, suggesting a link between these biomarkers and the spread of -syn aggregates [39]. These findings underscore the role of CSF biomarkers in diagnosing and monitoring synucleinopathy progression.

Lesion network mapping has elucidated the networks associated with neuropsychiatric symptoms in synucleinopathies, offering new perspectives on treatment targets [24]. By identifying common networks disrupted by -syn pathology, researchers can develop targeted interventions to halt or slow the spread of aggregates within the brain. A comprehensive understanding of the mechanisms involved in the transmission and spread of -synuclein pathology is essential for developing targeted therapeutic strategies that can effectively halt disease progression and enhance patient outcomes in synucleinopathies. Given that -synuclein pathology is a key factor in neurodegeneration, interventions addressing both the initial pathological misfolding and subsequent cell-to-cell transmission of -synuclein are critical [17, 4].

4 Impact on the Autonomic Nervous System

4.1 The Autonomic Nervous System and Neurodegeneration

The autonomic nervous system (ANS) is fundamental for maintaining physiological balance, regulating involuntary functions such as heart rate and digestion. Its dysfunction is prevalent in neurodegenerative diseases like Parkinson's disease (PD) and multiple system atrophy (MSA), where alpha-synuclein (-syn) aggregation plays a pivotal role [40]. -Syn deposits extend to peripheral autonomic neurons, aggravating autonomic dysfunction and advancing disease [41]. These aggregates in autonomic structures may serve as early biomarkers for neurodegenerative diseases, as autonomic symptoms often manifest before motor symptoms in PD [42]. Neuroinflammation is integral to PD pathophysiology, with PPAR agonists showing neuroprotective effects by enhancing mitochondrial function and reducing inflammation, suggesting therapeutic pathways for ANS dysfunction in PD models [30]. The early occurrence of autonomic symptoms, such as hyposmia, highlights the ANS's critical role in the initial stages of neurodegenerative diseases and its diagnostic potential [8].

Advanced methodologies like network analysis reveal the complex dynamics of brain networks, emphasizing the ANS's functional integrity in assessing neurodegenerative disease progression [18, 43]. Despite these advancements, challenges remain in comprehensively understanding -syn's interactions within the ANS and its toxicity mechanisms [37]. Addressing these challenges is crucial for developing targeted interventions to mitigate ANS dysfunction and improve clinical outcomes for synucleinopathy patients.

4.2 Role of the Gut-Brain Axis

The gut-brain axis is a bidirectional communication network connecting the central nervous system (CNS) with the enteric nervous system, integrating neural, hormonal, and immunological signals. In synucleinopathies like Parkinson's disease (PD), this axis is crucial, particularly regarding the microbiota's role in neurodegenerative processes. Dysbiosis, or gut microbiota disruption, is implicated in PD pathophysiology by influencing neuroinflammation and -syn aggregation [22, 6, 17, 4, 26]. -Syn is central to these disorders, contributing to gastrointestinal and neurological symptoms.

Research suggests -syn pathology may originate in the gastrointestinal tract, with misfolded -syn potentially spreading to the brain via the vagus nerve, a key gut-brain axis pathway. This prion-like transmission of pathological -syn is thought to initiate neuronal dysfunction and degeneration, correlating with PD's clinical manifestations [6, 4]. The presence of -syn aggregates in the gastrointestinal tract supports the hypothesis that the gut may serve as an entry point for environmental factors influencing disease pathogenesis.

Microglia, the CNS's resident immune cells, play a crucial role in neuroinflammation and gut-brain axis dysfunctions. Their interactions with -syn are significant in modulating inflammatory responses linked to autonomic nervous system dysfunctions observed in synucleinopathies [7]. This interplay suggests targeting neuroinflammation may offer therapeutic potential for gut-brain axis dysfunction.

The gut microbiota significantly influences -syn aggregation and neuroinflammation, exacerbating neurodegenerative processes. Dysbiosis is associated with various neurological disorders, indicating that gut microbiota-immune system interactions may initiate or worsen neurodegeneration through mechanisms like promoting amyloid formation and enhancing inflammatory responses [22, 44, 45, 26]. Observations of dysbiosis in PD patients suggest alterations in gut microbiota composition may worsen -syn pathology and disease progression, underscoring the need for further research into microbiota-targeted therapies.

Understanding the interplay between the gut-brain axis and -synuclein pathology is crucial for elucidating the complex mechanisms underlying synucleinopathies, including PD. The microbiota-gut-brain axis facilitates communication influencing both neurological health and neurodegenerative disease progression. As illustrated in Figure 4, the figure highlights the role of the gut-brain axis in synucleinopathies, emphasizing the microbiota's influence on neuroinflammation and -synuclein aggregation, the origins and pathways of -syn pathology, and potential therapeutic strategies targeting these interactions. Investigating these connections could lead to innovative therapeutic strategies aimed at addressing the root causes of these conditions rather than merely alleviating symptoms [6, 13, 4, 26, 46]. By elucidating these interactions, researchers can develop novel therapeutic strategies to modulate gut-brain communication, alleviating both gastrointestinal and neurological symptoms in affected individuals.



Figure 4: This figure illustrates the role of the gut-brain axis in synucleinopathies, highlighting the microbiota's influence on neuroinflammation and -synuclein aggregation, the origins and pathways of -syn pathology, and potential therapeutic strategies targeting these interactions.

5 Brain Connectivity and the Connectome

5.1 Dynamic Modeling of Brain Networks

Dynamic modeling of brain networks is essential for understanding neural connectivity alterations linked to alpha-synuclein (-syn) pathology. This approach uses computational techniques to analyze interactions within the brain's connectome, revealing -syn's impact on neural communication pathways. Researchers utilize a human connectome network with 998 nodes, employing models like the noisy Kuramoto model to study synchronization dynamics, capturing neural synchrony's temporal evolution [47]. Graph neural networks (GNNs) are pivotal in predicting disease outcomes from connectome data, using message-passing models to interpret connectivity changes due to -syn pathology. These models correlate specific network alterations with synucleinopathy progression, aiding therapeutic target identification [48]. Manifold learning enhances the visualization and interpretation of brain connectivity data, enriching the understanding of neural connections in neurodegenerative diseases [49]. Network object statistics (NOS) identify and test subnetworks, bolstering statistical inference through graph combinatorics [50]. Computational models simulating lesions on a 998-node network provide insights into brain networks' resilience and vulnerability under pathological conditions [51]. The dynamic connectome approach, integrating structural, functional, and effective connectivity methods, offers a comprehensive view of brain connectivity [52]. By employing advanced modeling techniques, researchers gain insights into structural and functional connectivity changes associated with -syn, paving the way for improved diagnostic and therapeutic strategies in synucleinopathies.

5.2 Techniques for Analyzing Brain Connectivity

Advancements in brain connectivity analysis techniques have significantly deepened our understanding of neural networks and their alterations in synucleinopathies. Diffusion MRI (dMRI) is a key technique mapping water molecule diffusion to elucidate structural brain connectivity. A dataset from 392 healthy subjects, yielding 1015-vertex graphs, showcases its utility in connectomics research [53]. Visualization techniques are crucial for mapping and interpreting neuronal circuits and brain function,

Benchmark	Size	Domain	Task Format	Metric
C2I[53]	70,652	Neuroscience	Graph-based Connectivity Analysis	F
NeuroConnect[54]	180,000	Neuroscience	Network Reconstruction	AUC, AUPR
MTB[55]	100,000	Classification	Classification	Accuracy, F1-score
MSA-QoL[8]	1,537	Neurodegenerative Disease	Quality OF Life Assessment	Hr-QoL
EEG-PD[56]	30	Neurology	Classification	Accuracy, Precision

Table 1: Table of representative benchmarks used in the analysis of brain connectivity, detailing the size, domain, task format, and evaluation metrics for each dataset. These benchmarks include datasets from neuroscience and neurology, focusing on tasks such as graph-based connectivity analysis, network reconstruction, classification, and quality of life assessment.

revealing insights into the brain's functional and structural organization [57]. These tools identify connectivity profiles linked to clinical outcomes, such as those measured by the Unified Parkinson Disease Rating Scale (UPDRS), and assess prediction accuracy through leave-one-cohort-out designs [58]. Machine learning integration with connectomic data refines brain network analysis, identifying significant subnetworks associated with neurological conditions, enhancing diagnostic and treatment strategies for synucleinopathies [48]. Algorithms distinguish true connections from false ones, employing metrics quantifying algorithmic effectiveness [54]. K-partite graph detection (KPGD) uncovers k-partite graph structures in connectivity data, identifying differentially expressed edges within a network [59]. Group label permutation and graph edge permutation tests assess statistical significance in connectivity analyses, focusing on identified subnetworks [50]. Collectively, these techniques enhance understanding of brain connectivity and disruptions linked to synucleinopathies, particularly Parkinson's disease. Table 1 provides a detailed overview of the representative benchmarks employed in brain connectivity analysis, highlighting the diversity in dataset sizes, domains, task formats, and evaluation metrics. This comprehensive approach elucidates alpha-synuclein's pathological role, including aggregation and transmission between neurons, highlighting potential therapeutic strategies like receptor blocking, immunotherapy, and autophagic process enhancement. Mapping these disruptions to brain networks identifies new intervention targets to modify disease progression and improve patient outcomes [18, 17, 24, 4, 60].

5.3 Hierarchical and Modular Organization of the Connectome

The hierarchical and modular organization of the connectome is fundamental to brain architecture, facilitating functional states through complex network dynamics. This organization features small-world, scale-free, and hierarchical network archetypes, enabling efficient information processing and maintaining cognitive and motor functions [61, 62]. In synucleinopathies, connectome structural organization disruption leads to altered brain dynamics and connectivity. The hierarchical modular organization contributes to an intermediate synchronization phase crucial for accessing functional states without fine-tuning [63]. Synchronization in hierarchical modular networks is modeled using the Kuramoto model, illustrating synchronization emergence [47]. Such models position dynamic connectomes as more accurate biomarkers for brain diseases, reflecting brain dynamics' variability and adaptability more effectively than static structural connectomes [52]. Synucleinopathies profoundly impact the connectome, with targeted damage to high-weight connections leading to a sub-critical state characterized by reduced activity and slower fluctuations [51]. This state indicates the brain's compromised ability to maintain normal dynamic function, underscoring hierarchical organization in sustaining neural health. Additionally, nanoscale organization and diffusivity alterations within the extracellular space (ECS) in synucleinopathies facilitate neurodegenerative pathology spread [25]. Understanding the connectome's structural organization and its alterations in disease states provides insights into synucleinopathies' mechanisms and potential therapeutic interventions. Leveraging advanced visualization techniques and integrating multimodal data enhances understanding of the connectome's hierarchical and modular organization, leading to more effective synucleinopathy management strategies.

5.4 The Role of Biomarkers and Visualization in Connectome Research

Biomarkers are critical indicators of neural network changes in neurodegenerative diseases, offering insights into synucleinopathy progression and facilitating early diagnosis and targeted interventions. Advanced visualization techniques enhance connectome dynamics understanding by providing de-

tailed representations of the brain's intricate network architecture. These techniques analyze neuronal connections essential for mapping the complete connectome and identifying meaningful patterns across populations, supporting clinical diagnoses and treatments for neuropsychiatric disorders. Tools like NeuroCave enable exploration of both topological and spatial brain network features, revealing how functional brain states arise from anatomical structures and informing interventions for conditions like schizophrenia and autism [64, 57, 61]. Manifold learning techniques, including the Covariate-Conditioned Manifold Learning (CCML) method, integrate covariates into brain connectivity analyses, providing nuanced insights into connectome changes [49]. This approach emphasizes biomarkers' potential to identify neural network alterations, contributing to a deeper understanding of disease mechanisms. The spatial organization and topological features of neural networks are vital for characterizing the connectome, influencing the brain's functional capabilities and resilience to pathology [61]. Standardized methods in connectome analysis ensure consistency and reliability in research findings, enabling dataset comparisons across clinical settings. Visualization tools like NeuroCave offer immersive web-based platforms for analyzing and comparing connectome datasets, enhancing complex data interpretation in clinical environments [64]. These tools facilitate connectome topology exploration, enabling researchers to identify significant patterns and deviations associated with neurodegenerative disorders. Integrating experimental data with structural models of neurodegeneration-linked proteins, achieved through approaches like Hybrid Computational Geometry (HCG), refines understanding of protein structures and their impact on the connectome [65]. This integration highlights the importance of combining experimental and computational techniques to advance connectome research. The convergence of biomarkers and advanced visualization techniques plays a pivotal role in connectome research, significantly enhancing understanding of neural network alterations related to neurodegenerative diseases. By mapping intricate brain connections, these tools facilitate disorder-specific biomarker identification and promote targeted diagnostic and therapeutic strategy development. The application of dynamic connectomes and innovative visualization tools, such as NeuroCave, enables researchers to uncover meaningful patterns in brain connectivity, improving diagnosis accuracy and treatment approaches for various neuropsychiatric disorders [57, 66, 43, 64, 52]. Leveraging these tools will ultimately enhance diagnostic and therapeutic strategies, improving patient outcomes.

6 Therapeutic Approaches and Future Directions

6.1 Therapeutic Strategies and Challenges

Therapeutic strategies for synucleinopathies, particularly Parkinson's disease (PD), center on targeting alpha-synuclein (-syn) to mitigate its pathological effects. Key approaches include inhibiting -syn aggregation, enhancing its clearance, and employing immunotherapy, each targeting distinct aspects of -syn pathology. Notably, graphene quantum dots (GQDs) demonstrate potential in preventing -syn fibrillization and promoting disaggregation [41]. Understanding the balance between beneficial and toxic -syn forms is crucial, necessitating further exploration of -syn oligomer structures and their membrane interactions.

Enhancing -syn clearance via autophagic and proteasomal pathways presents another promising strategy. The lysosomal exocytosis pathway offers a novel mechanism for expelling pathogenic proteins, suggesting new therapeutic targets [38]. Immunotherapy targeting Toll-like receptor 2 (TLR2) aims to modulate immune responses, potentially offering advantages over non-specific treatments. Additionally, the activation of the DNA damage response (DDR) by -syn stress implies that enhancing DNA repair mechanisms could be viable for PD treatment [2].

Integrating multiple modalities in biomarker research is vital for improving therapeutic development. Current studies often lack a comprehensive approach, focusing on isolated biomarkers. Future research should incorporate high-resolution imaging data and consider individual neural response variations, particularly in personalized medicine for PD, facilitating early diagnosis and treatment planning [23].

Despite progress, -syn's specificity and reliability as a biomarker need further validation through extensive studies to ensure clinical efficacy. Current research limitations in PD include an incomplete understanding of -syn transmission and significant variability in therapeutic responses, complicating treatment development [17, 18]. Addressing these challenges requires a deeper understanding of -syn's role in synucleinopathies and the integration of innovative research methodologies.

6.2 Emerging Research Directions

Emerging research in synucleinopathies increasingly utilizes advanced technologies to enhance understanding and treatment. A key focus is developing sophisticated models to study -syn's role in neurodegeneration and explore therapeutic strategies targeting its aggregation, including methods for oligomer detection and novel therapeutic approaches [10].

Artificial intelligence and machine learning, such as pre-training and transfer learning, hold promise for improving model performance and developing therapies targeting -syn-related disease progression [29]. Expanding benchmarks with diverse tasks and datasets, and exploring different model architectures, can deepen understanding of -syn's effects.

Clarifying -syn's molecular interactions with cellular membranes, especially regarding PD-related mutants, remains a priority. Identifying potential drug targets to mitigate -syn toxicity is crucial [4]. Additionally, exploring gut microbiota modulation and its interplay with diet and neurodegenerative diseases presents a promising research area.

Refining methods to explore the conformational dynamics of natively unstructured proteins like -syn and evaluating pharmacological agents targeting specific conformational equilibria are promising avenues. Larger studies are needed to validate cerebrospinal fluid (CSF) biomarkers and assess their potential in guiding therapies [4].

Future research should elucidate -syn toxicity mechanisms and develop biomarkers for early diagnosis and targeted therapies. Understanding microglia's diverse roles across neurodegenerative contexts and exploring novel therapeutic approaches to target microglial functions is essential [45].

Cross-disorder studies are vital for identifying common connectome fingerprints, utilizing big data and computational models to enhance understanding of brain connectivity and its treatment implications [24]. Developing frameworks for network analysis and validating network statistics in clinical settings remain essential [49].

Utilizing multi-modal MRI data could enhance understanding of developmental and aging trajectories in brain connectivity [23]. Large-scale studies are necessary to validate biomarkers and explore integrating -syn with other biomarkers to improve diagnostic accuracy. Identifying cofactors and modifications essential for -syn filament assembly in juvenile onset synucleinopathy (JOS) should be prioritized.

Future work could focus on incorporating realistic elements into models, such as explicit phase lags or time delays, to explore structural frustration implications on synchronization dynamics. Extending frameworks to include subcortical and white matter regions, examining longitudinal changes in cortical geometry, and developing machine learning models to enhance diagnostics are promising directions. Additionally, developing better preclinical models mimicking human PD pathology and conducting extended clinical trials to evaluate PPAR agonists' long-term effects on PD progression are priorities [28].

These collective efforts aim to enhance understanding of -syn's role in neurodegenerative diseases like Parkinson's disease, affecting over 10 million individuals globally and imposing significant economic burdens. By identifying knowledge gaps and employing a multipronged research strategy, these initiatives aspire to develop innovative diagnostic tools and therapies addressing -syn toxicity mechanisms, including aggregation, cellular spread, and pathway disruption. This comprehensive research endeavor seeks to yield disease-modifying therapies that could significantly alter Parkinson's disease progression and improve patient outcomes [17, 60].

7 Conclusion

The aggregation of alpha-synuclein (-syn) is central to the pathogenesis of neurodegenerative disorders, notably impacting the autonomic nervous system and neural connectivity. This survey highlights -syn's complex role in diseases such as Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies, where its aggregation disrupts cellular equilibrium and promotes neurotoxic propagation across neural circuits. Understanding these mechanisms is vital for deciphering disease progression.

Advancing therapeutic strategies necessitates a multifaceted approach. Recognizing microbial amyloids as contributors to neurodegenerative diseases suggests novel therapeutic targets within the microbiome, emphasizing the importance of comprehensive treatment methodologies. Additionally, the interaction of -syn with cellular membranes, influenced by lipid concentrations, underscores the intricacy of its role in amyloid formation, which is critical for developing effective interventions.

Future research should focus on refining experimental models and expanding imaging biomarker studies to validate findings across diverse populations, thereby improving early-stage Parkinson's disease classification accuracy. Integrating brain connectivity analyses with regional EEG data offers a promising direction for enhancing both diagnostic and therapeutic approaches.

References

[1] Alpha-synuclein aggregation in p.

[2] Chiara Milanese, Silvia Cerri, Ayse Ulusoy, Simona V Gornati, Audrey Plat, Sylvia Gabriels, Fabio Blandini, Donato A Di Monte, Jan H Hoeijmakers, and Pier G Mastroberardino. Activation of the dna damage response in vivo in synucleinopathy models of parkinson's disease. *Cell death & disease*, 9(8):818, 2018.

[3] W. Wendell Smith, Carl F. Schreck, Nabeem Hashem, Sherwin Soltani, Abhinav Nath, Elizabeth Rhoades, and Corey S. O'Hern. Molecular simulations of the fluctuating conformational dynamics of intrinsically disordered proteins, 2012.

[4] Michael X Henderson, John Q Trojanowski, and Virginia M-Y Lee. α-synuclein pathology in parkinson's disease and related α-synucleinopathies. *Neuroscience letters*, 709:134316, 2019.

[5] Dániel L Barabási, Ginestra Bianconi, Ed Bullmore, Mark Burgess, SueYeon Chung, Tina Eliassi-Rad, Dileep George, István A. Kovács, Hernán Makse, Christos Papadimitriou, Thomas E. Nichols, Olaf Sporns, Kim Stachenfeld, Zoltán Toroczkai, Emma K. Towlson, Anthony M Zador, Hongkui Zeng, Albert-László Barabási, Amy Bernard, and György Buzsáki. Neuroscience needs network science, 2023.

[6] Veronica Ghiglieri, Valeria Calabrese, and Paolo Calabresi. Alpha-synuclein: from early synaptic dysfunction to neurodegeneration. *Frontiers in neurology*, 9:295, 2018.

[7] Guoxin Zhang, Yun Xia, Fang Wan, Kai Ma, Xingfang Guo, Liang Kou, Sijia Yin, Chao Han, Ling Liu, Jinsha Huang, et al. New perspectives on roles of alpha-synuclein in parkinson's disease. *Frontiers in aging neuroscience*, 10:370, 2018.

[8] Tiphaine Saulnier, Margherita Fabbri, Mélanie Le Goff, Catherine Helmer, Anne Pavy-Le Traon, Wassilios G. Meissner, Olivier Rascol, Cécile Proust-Lima, and Alexandra Foubert-Samier. Patient-perceived progression in multiple system atrophy: natural history of quality of life, 2023.

[9] Luis D Bernal-Conde, Rodrigo Ramos-Acevedo, Mario A Reyes-Hernández, Andrea J Balbuena-Olvera, Ishbelt D Morales-Moreno, Rubén Argüero-Sánchez, Birgitt Schüle, and Magdalena Guerra-Crespo. Alpha-synuclein physiology and pathology: a perspective on cellular structures and organelles. *Frontiers in Neuroscience*, 13:1399, 2020.

[10] Jeswinder Sian-Hulsmann and Peter Riederer. The 'α-synucleinopathy syndicate': multiple system atrophy and parkinson's disease. *Journal of Neural Transmission*, 131(6):585–595, 2024.

[11] Weikai Li, Yongxiang Tang, Zhengxia Wang, Shuo Hu, and Xin Gao. The reconfiguration pattern of individual brain metabolic connectome for parkinson's disease identification, 2021.

[12] Martijn P van den Heuvel and Olaf Sporns. A cross-disorder connectome landscape of brain dysconnectivity. *Nature reviews neuroscience*, 20(7):435–446, 2019.

[13] Richard M Meade, David P Fairlie, and Jody M Mason. Alpha-synuclein structure and parkinson's disease–lessons and emerging principles. *Molecular neurodegeneration*, 14:1–14, 2019.

[14] Brittany Butler, Danielle Sambo, and Habibeh Khoshbouei. Alpha-synuclein modulates dopamine neurotransmission. *Journal of chemical neuroanatomy*, 83:41–49, 2017.

[15] Mitchell G Miglis, Charles H Adler, Elena Antelmi, Dario Arnaldi, Luca Baldelli, Bradley F Boeve, Matteo Cesari, Irene Dall'Antonia, Nico J Diederich, Kathrin Doppler, et al. Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. *The Lancet Neurology*, 20(8):671–684, 2021.

[16] Hina Shaheen and Roderick Melnik. Bayesian approaches for revealing complex neural network dynamics in parkinson's disease, 2024.

[17] Luis MA Oliveira, Thomas Gasser, Robert Edwards, Markus Zweckstetter, Ronald Melki, Leonidas Stefanis, Hilal A Lashuel, David Sulzer, Kostas Vekrellis, Glenda M Halliday, et al. Alpha-synuclein research: defining strategic moves in the battle against parkinson's disease. *npj Parkinson's Disease*, 7(1):65, 2021.

[18] John D. Medaglia and Danielle S. Bassett. Network analyses and nervous system disorders, 2017.

[19] Elena Righetti, Alice Antonello, Luca Marchetti, Enrico Domenici, and Federico Reali. Mechanistic models of α-synuclein homeostasis for parkinson's disease: A blueprint for therapeutic intervention, 2022.

[20] Jeffrey Gu, Julio Barrera, Young Yun, Susan K Murphy, Thomas G Beach, Randy L Woltjer, Geidy E Serrano, Boris Kantor, and Ornit Chiba-Falek. Cell-type specific changes in dna methylation of snca intron 1 in synucleinopathy brains. *Frontiers in neuroscience*, 15:652226, 2021.

[21] Amanmeet Garg, Donghuan Lu, Karteek Popuri, and Mirza Faisal Beg. Cortical geometry network and topology markers for parkinson's disease, 2016.

[22] Robert P Friedland and Matthew R Chapman. The role of microbial amyloid in neurodegeneration. *PLoS pathogens*, 13(12):e1006654, 2017.

[23] Tanmayee Samantaray, Utsav Gupta, Jitender Saini, and Cota Navin Gupta. Unique brain network identification number for parkinson's individuals using structural mri, 2023.

[24] Michael D Fox. Mapping symptoms to brain networks with the human connectome. *New England Journal of Medicine*, 379(23):2237–2245, 2018.

[25] Federico N Soria, Chiara Paviolo, Evelyne Doudnikoff, Marie-Laure Arotcarena, Antony Lee, Noémie Danné, Amit Kumar Mandal, Philippe Gosset, Benjamin Dehay, Laurent Groc, et al. Synucleinopathy alters nanoscale organization and diffusion in the brain extracellular space through hyaluronan remodeling. *Nature communications*, 11(1):3440, 2020.

[26] Emily Fitzgerald, Sarah Murphy, and Holly A Martinson. Alpha-synuclein pathology and the role of the microbiota in parkinson's disease. *Frontiers in neuroscience*, 13:369, 2019.

[27] Donghoon Kim, Je Min Yoo, Heehong Hwang, Junghee Lee, Su Hyun Lee, Seung Pil Yun, Myung Jin Park, MinJun Lee, Seulah Choi, Sang Ho Kwon, Saebom Lee, Seung-Hwan Kwon, Sangjune Kim, Yong Joo Park, Misaki Kinoshita, Young-Ho Lee, Seokmin Shin, Seung R. Paik, Sung Joong Lee, Seulki Lee, Byung Hee Hong, and Han Seok Ko. Graphene quantum dots prevent alpha-synucleinopathy in parkinson's disease, 2018.

[28] Brian Spencer, Elvira Valera, Edward Rockenstein, Cassia Overk, Michael Mante, Anthony Adame, Wagner Zago, Peter Seubert, Robin Barbour, Dale Schenk, et al. Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy. *Acta neuropathologica communications*, 5:1–15, 2017.

[29] Gary B. Huang, Louis K. Scheffer, and Stephen M. Plaza. Fully-automatic synapse prediction and validation on a large data set, 2016.

[30] Isaac Pérez-Segura, Alberto Santiago-Balmaseda, Luis Daniel Rodríguez-Hernández, Adriana Morales-Martínez, Hilda Angélica Martínez-Becerril, Paola A Martínez-Gómez, Karen M Delgado-Minjares, Citlaltepetl Salinas-Lara, Irma A Martínez-Dávila, Magdalena Guerra-Crespo, et al. Ppars and their neuroprotective effects in parkinson's disease: a novel therapeutic approach in α-synucleinopathy? *International Journal of Molecular Sciences*, 24(4):3264, 2023.

[31] Ricardo Guerrero-Ferreira, Nicholas MI Taylor, Daniel Mona, Philippe Ringler, Matthias E Lauer, Roland Riek, Markus Britschgi, and Henning Stahlberg. Cryo-em structure of alpha-synuclein fibrils. *elife*, 7:e36402, 2018.

[32] Massimo Sandal, Francesco Valle, Isabella Tessari, Stefano Mammi, Elisabetta Bergantino, Francesco Musiani, Marco Brucale, Luigi Bubacco, and Bruno Samori'. Conformational equilibria in monomeric alpha-synuclein at the single molecule level, 2007.

[33] Mattia Vicario, Domenico Cieri, Marisa Brini, and Tito Calì. The close encounter between alpha-synuclein and mitochondria. *Frontiers in Neuroscience*, 12:388, 2018.

[34] Cencen Liu, Yunfei Zhao, Huan Xi, Jie Jiang, Yang Yu, and Wei Dong. The membrane interaction of alpha-synuclein. *Frontiers in cellular neuroscience*, 15:633727, 2021.

[35] Tanmayee Samantaray, Jitender Saini, Pramod Kumar Pal, Bithiah Grace Jaganathan, Vijaya V Saradhi, and Gupta CN. Labeling subtypes in a parkinson's cohort using multifeatures in mri – integrating grey and white matter information, 2024.

[36] Cécile Proust-Lima, Tiphaine Saulnier, Viviane Philipps, Anne Pavy-Le Traon, Patrice Péran, Olivier Rascol, Wassilios G Meissner, and Alexandra Foubert-Samier. Describing complex disease progression using joint latent class models for multivariate longitudinal markers and clinical endpoints, 2023.

[37] Yang Yang, Holly J Garringer, Yang Shi, Sofia Lövestam, Sew Peak-Chew, Xianjun Zhang, Abhay Kotecha, Mehtap Bacioglu, Atsuo Koto, Masaki Takao, et al. New snca mutation and structures of α-synuclein filaments from juvenile-onset synucleinopathy. *Acta Neuropathologica*, 145(5):561–572, 2023.

[38] Ying Xue Xie, Nima N Naseri, Jasmine Fels, Parinati Kharel, Yoonmi Na, Diane Lane, Jacqueline Burré, and Manu Sharma. Lysosomal exocytosis releases pathogenic α-synuclein species from neurons in synucleinopathy models. *Nature communications*, 13(1):4918, 2022.

[39] David J Irwin, Sharon X Xie, David Coughlin, Naomi Nevler, Rizwan S Akhtar, Corey T McMillan, Edward B Lee, David A Wolk, Daniel Weintraub, Alice Chen-Plotkin, et al. Csf tau and β-amyloid predict cerebral synucleinopathy in autopsied lewy body disorders. *Neurology*, 90(12):e1038–e1046, 2018.

[40] Patrick Glatte, Sylvia J Buchmann, Mido Max Hijazi, Ben Min-Woo Illigens, and Timo Siepmann. Architecture of the cutaneous autonomic nervous system. *Frontiers in neurology*, 10:970, 2019.

[41] Donghoon Kim, Je Min Yoo, Heehong Hwang, Junghee Lee, Su Hyun Lee, Seung Pil Yun, Myung Jin Park, MinJun Lee, Seulah Choi, Sang Ho Kwon, et al. Graphene quantum dots prevent α-synucleinopathy in parkinson's disease. *Nature nanotechnology*, 13(9):812–818, 2018.

[42] Yuanyuan Li, Wenyan Kang, Qiong Yang, Lina Zhang, Linyuan Zhang, Fangyi Dong, Shengdi Chen, and Jun Liu. Predictive markers for early conversion of irbd to neurodegenerative synucleinopathy diseases. *Neurology*, 88(16):1493–1500, 2017.

[43] Jacob Adamczyk. Neural network degeneration and its relationship to the brain, 2020.

[44] Marco Colonna and Oleg Butovsky. Microglia function in the central nervous system during health and neurodegeneration. *Annual review of immunology*, 35(1):441–468, 2017.

[45] Weifeng Zhang, Dan Xiao, Qinwen Mao, and Haibin Xia. Role of neuroinflammation in neurodegeneration development. *Signal transduction and targeted therapy*, 8(1):267, 2023.

[46] Naomi P Visanji, Anthony E Lang, and Gabor G Kovacs. Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities. *Translational neurodegeneration*, 8:1–13, 2019.

[47] Pablo Villegas, Jorge Hidalgo, Paolo Moretti, and Miguel A. Muñoz. Complex synchronization patterns in the human connectome network, 2016.

[48] Colin J Brown and Ghassan Hamarneh. Machine learning on human connectome data from mri, 2016.

[49] Félix Renard, Christian Heinrich, Marine Bouthillon, Maleka Schenck, Francis Schneider, Stéphane Kremer, and Sophie Achard. Manifold learning for brain connectivity, 2020.

[50] Shuo Chen, Yishi Xing, Jian Kang, Dinesh Shukla, Peter Kochunov, and L. Elliot Hong. A network object method to uncover hidden disorder-related brain connectome, 2017.

[51] Ariel Haimovici, Pablo Balenzuela, and Enzo Tagliazucchi. Dynamical signatures of structural connectivity damage to a model of the brain posed at criticality, 2016.

[52] Marcus Kaiser. The potential of the human connectome as a biomarker of brain disease, 2013.

[53] Csaba Kerepesi, Balázs Szalkai, Bálint Varga, and Vince Grolmusz. Comparative connectomics: Mapping the inter-individual variability of connections within the regions of the human brain, 2015.

[54] Bisakha Ray, Alexander V. Alekseyenko, Sisi Ma, Alexander Statnikov, and Constantin Aliferis. Evaluation and ensembling of methods for reverse engineering of brain connectivity from imaging data, 2016.

[55] Xin Ma, Guorong Wu, Seong Jae Hwang, and Won Hwa Kim. Learning multi-resolution graph edge embedding for discovering brain network dysfunction in neurological disorders, 2024.

[56] Amarpal Sahota, Amber Roguski, Matthew W Jones, Zahraa S. Abdallah, and Raul Santos-Rodriguez. Investigating brain connectivity and regional statistics from eeg for early stage parkinson's classification, 2024.

[57] Hanspeter Pfister, Verena Kaynig, Charl P. Botha, Stefan Bruckner, Vincent J. Dercksen, Hans-Christian Hege, and Jos B. T. M. Roerdink. Visualization in connectomics, 2012.

[58] <div style="text-align: center;".

[59] Shuo Chen, F. DuBois Bowman, and Yishi Xing. Differentially expressed functional connectivity networks with k-partite graph topology, 2016.

[60] Carroll Rutherford Fields, Nora Bengoa-Vergniory, and Richard Wade-Martins. Targeting alpha-synuclein as a therapy for parkinson's disease. *Frontiers in molecular neuroscience*, 12:299, 2019.

[61] Marcus Kaiser. A tutorial in connectome analysis: Topological and spatial features of brain networks, 2011.

[62] Jinseop S. Kim and Marcus Kaiser. From caenorhabditis elegans to the human connectome: A specific modular organisation increases metabolic, functional, and developmental efficiency, 2014.

[63] Pablo Villegas, Paolo Moretti, and Miguel A. Muñoz. Frustrated hierarchical synchronization and emergent complexity in the human connectome network, 2014.

[64] Johnson J. G. Keiriz, Liang Zhan, Morris Chukhman, Olu Ajilore, Alex D. Leow, and Angus G. Forbes. Exploring the human connectome topology in group studies, 2017.

[65] Lisa M. Pietrek, Lukas S. Stelzl, and Gerhard Hummer. Structural ensembles of disordered proteins from hierarchical chain growth and simulation, 2022.

[66] Hejie Cui, Wei Dai, Yanqiao Zhu, Xiaoxiao Li, Lifang He, and Carl Yang. Interpretable graph neural networks for connectome-based brain disorder analysis, 2022.

Disclaimer:

SurveyX is an AI-powered system designed to automate the generation of surveys. While it aims to produce high-quality, coherent, and comprehensive surveys with accurate citations, the final output is derived from the AI's synthesis of pre-processed materials, which may contain limitations or inaccuracies. As such, the generated content should not be used for academic publication or formal submissions and must be independently reviewed and verified. The developers of SurveyX do not assume responsibility for any errors or consequences arising from the use of the generated surveys.